Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy went more than twice as long without their disease worsening compared with those who received SBRT alone, according to new clinical trial results from UCLA Health Jonsson Comprehensive Cancer Center researchers.
UC Davis Health and UCLA are co-leading a newly funded national clinical trial to evaluate whether AI can help radiologists interpret screening mammograms more accurately. The goal is to improve breast cancer detection and reduce unnecessary callbacks and anxiety for patients.
